Amgen is paying a premium to buy the small biotech.
News & Analysis: Five Prime Therapeutics
This tiny biotech might be developing a major new cancer drug.
Biotech investors had more than just vaccines to think about this year.
Aptose Biosciences and Five Prime Therapeutics both have explosive growth potential.
And as a bonus, find out which much-loved stock let its shareholders down.
The biotech's stomach cancer drug hit the mark in a midstage trial.
FPRX earnings call for the period ending March 31, 2019.
FPRX earnings call for the period ending December 31, 2018.
Five Prime Therapeutics and Bristol-Myers Squibb may have a viable pancreatic cancer drug after all.
A key development deal with a leader in immuno-oncology sent shares higher last month.